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Abstract
Study Objective—To categorize institutional review board (IRB) challenges and solutions
encountered in a multicenter, practice-based research network (PBRN) study and to assess the
impact of IRB requirements on individual principal investigators’ (PIs’) willingness to participate
in future PBRN studies.
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Design—Descriptive analysis of IRB challenges and solutions encountered in the Collaboration
Among Pharmacists and Physicians To Improve Outcomes Now (CAPTION) study—a
multicenter, prospective, cluster-randomized study conducted by the National Interdisciplinary
Primary Care PBRN—and a correlational analysis from a survey of individual site PIs.
Measurements and main results—IRB barriers encountered and solutions were categorized
for study sites. A survey of study-site PIs was conducted with a correlational analysis assessing
the impact of various IRB requirements and individual PIs’ willingness to participate in future
PBRN studies; of 31 study sites participating in the CAPTION study, 28 study-site PIs were
surveyed. IRBs posed a number of challenges, including bias regarding the source of the
application, issues regarding study design, study instruments, access to patient records, study
procedures, Spanish-only speaking subjects, role of clinic physicians, interdepartmental concerns,
and updates at continuing review. Responses from the PI survey (21 of 28 PIs surveyed [75%
response rate]) indicated that the willingness of an individual to serve as a PI in the future was
inversely related to the perceived difficulty of obtaining initial (rS = −0.599, p = 0.004) and
continuing (rS = −0.464, p = 0.034) IRB approval.
Conclusion—Significant time and resources were required to address various challenges
associated with IRB approval, which negatively impacted an individual PI’s willingness to
participate in future PBRN projects. A revision of current rules and regulations regarding human
subjects protection for practice-based studies, improvement in IRB processes, and support from
coordinating centers may decrease the burden associated with IRB approval and increase
participation in practice-based research.
Keywords
institutional review board; IRB; barriers; practice-based research network
The vast majority of medical care delivered in the United States occurs in nonacademic,
community settings. In fact, 21.7% of individuals who responded to a telephone survey
conducted in 2000 had sought care during the previous month in a primary care or specialty
clinic, whereas less than 0.01% had been admitted to an academic medical center hospital.1
Remarkably, this distribution has changed little over the past 40 years.2 Considering that the
majority of medical research is conducted in academic medical centers, yet most care
actually occurs in nonacademic, primary care settings, questions persist regarding the
external validity and real-world effectiveness of various interventions.
Practice-Based Research Networks (PBRNs) were developed to bridge the divide between
where medical research is conducted and where the results are used in practice.3 The
Agency for Healthcare Research and Quality (AHRQ) defines a PBRN as a group of at least
15 primary care practices devoted principally to the care of patients that seeks to “expand
the science base of clinical care through systematic inquiry to better understand the health
and health care events that unfold daily in their community practice settings.”4 Beginning in
the late 1970s and 1980s, and with support by the federal government, the number and types
of PBRNs have grown significantly, with 162 primary care PBRNs currently registered with
AHRQ.5, 6
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The National Interdisciplinary Primary Care Practice–Based Research Network
(NIPCPBRN) was founded in 2007 with its mission to “study interdisciplinary team–based
care of chronic medical conditions, with emphasis on the development of strategies to
improve national guideline adherence.”7 Over the past four years, the NIPC-PBRN has been
engaged in a large, national, cluster-randomized effectiveness trial—the Collaboration
Among Pharmacists and Physicians to Improve Outcomes Now (CAPTION) trial—
evaluating a team-based approach to care involving a physician and pharmacist in the
management of hypertension or asthma that could be scaled up and implemented on a larger
scale.8 The CAPTION study has encountered multiple challenges associated with the
institutional review board (IRB) approval process. IRB review and approval is critical to
ensure that human research is conducted in an ethical manner and that patient rights and
safety are protected. However, the regulatory challenges posed by multicenter research
projects can often be daunting. Although IRBs have a common set of rules and regulations
that must be followed,9 the interpretation and implementation of these regulations can be
extremely variable. Several studies on multicenter research have documented significant
variability among IRBs on a wide range of issues including study classification (e.g., exempt
vs. expedited vs. full IRB review),10-14 variations in consent requirements,10-18 methods
and/or issues related to subject recruitment,10, 17, 18 and length of time for
approval.10, 12, 14, 17, 18 These differences result in significant administrative burdens when
conducting multicenter research, particularly with regard to staff time and resources. A
recent study assessed the variability in IRB reviews for a multicenter, minimal-risk study of
financial incentives for evidence-based hypertension care that involved 25 Veteran Affairs
medical centers. It was estimated the time spent on administrative approval was 6,729 hours
and cost approximately $168,000 in staff salaries.14
While previous studies have described various challenges related to the IRB approval
process for multicenter studies, scant data are available that describe individual site principal
investigator (PI) opinions related to this process.19 The goal of the current study is to
describe IRB barriers encountered and to provide a correlational analysis regarding the
impact of various IRB administrative requirements and individual PIs’ willingness to
participate in future PBRN studies.
Methods
In this study, we describe the IRB challenges and resolutions encountered in the CAPTION
study and provide a correlational analysis of PI perceptions related to the IRB process and
willingness to participate in future PBRN projects. The CAPTION trial has been described
elsewhere.8 Briefly, 27 family medicine clinics, later expanded to 31 clinics with 28 PIs, that
employed clinical pharmacists located in 14 states were stratified, then randomized, to one
of 3 groups: 9-month physician-pharmacist collaborative model (PPCM) arm (n=216), 24-
month PPCM arm (n=216), or control group (n=216) that also included a distracter
intervention for asthma. The primary outcome measure for the study was to determine if the
PPCM model would lead to improved blood pressure or asthma control. Secondary
outcomes included comparison of blood pressure control among minorities (54% of the BP
study population) and those from lower socioeconomic groups, and the association between
blood pressure control rates and provider attitudes to the PPCM model.
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IRB approval was sought and granted from the primary sponsor recipient (University of
Iowa, Iowa City, IA). IRB submission material and forms (e.g., protocol, consent templates,
recruitment letter templates) were provided to collaborating investigators who sought IRB
approval through their own institutions. Research staff at the University of Iowa monitored
the approval process and documented regulatory issues or concerns from individual IRBs
when they occurred, as well as solutions or resolutions to encountered problems.
Next, all study PIs (n=28) were invited to complete an anonymous, 15-item Web-based
survey (Inquisite Survey, Austin, TX). The authors, who have significant experience in IRB-
related issues, developed the survey tool (e.g., content validity). Opinions regarding level of
difficulty with initial and continuing IRB approval, willingness to serve as a study PI or as a
collaborating investigator in a subsequent research endeavor, and general attitudes regarding
the IRB process and workload were assessed on a 5-point Likert scale (5=strongly agree,
4=agree, 3=neutral, 2=disagree, 1=strong disagree). In addition, basic demographic data
including type of position, prior experience as a PI, job expectations for research and/or
scholarship, administrative research support, type of IRB and submission system, and
estimated time required for initial and continuing review were obtained. Opportunities for
additional comments or opinions were provided as free-text fields. The Texas Tech
University Health Science Center Institutional Review Board (Amarillo, TX) approved the
survey study.
Statistical Analysis
Types of IRB barriers encountered and resolutions related to initial IRB approval and first
continuing review approval were collected and categorized by the primary sponsor recipient.
Data from the Web-based surveys were downloaded as a comma-separated values (CSV)
file. Data were then imported to SPSS software, version 19 (SPSS Inc., Chicago, IL) for
analysis. Descriptive statistics were used to describe PI and IRB characteristics. Spearman’s
correlation coefficient was used to compare all variables related to perceived level of
difficulty in obtaining initial and continuing IRB approval, willingness to participate again
in the CAPTION trial as either a PI or collaborating investigator, perceptions related to
navigating the IRB process, availability of research support, past experience as a PI or co-PI,
type of IRB system (e.g., computer- vs. paper-based), and estimated time spent on initial and
first continuing IRB approval. The Mann Whitney U test was used to determine whether
type of IRB (i.e., both university and hospital/health system versus others) was associated
with the time required for initial or continuing IRB approval and willingness to participate in
a future PBRN study.
Results
The CAPTION study received funding by the National Heart, Lung and Blood Institute
effective 4/15/2009 for both the Clinical Coordinating Center (CCC) and the Data
Coordinating Center. Each of the medical offices that agreed to serve as a performance site
for the study received a subcontract from the primary university. Each medical office named
a local site PI, lead physician, pharmacist (if not also the PI), and a study coordinator. Many
of the study coordinators were employees of the medical office and were assigned by the
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office to recruit and consent subjects and collect data as part of their clinic responsibilities.
Several university departments had research office staff that filled the study coordinator
position.
The CAPTION study was approved by the primary study sponsor’s IRB on 06/10/2009.
Submission materials and forms (e.g., protocol, consent templates, recruitment letter
templates) were distributed to the original subcontracted study sites (n=27) between
2/13/2009 and 5/9/2009. The first subcontracted study site received IRB approval on
4/10/2009 and the last on 12/28/2010. Due to challenges with IRB approvals that, in part,
delayed patient recruitment and enrollment, sites were expanded to a total of 31 sites with 28
PIs. The final newly added site received IRB approval on 4/27/2011. The study enrolled the
last patient (n=750) on March 29, 2012, approximately 9 months later than planned. These
delays and requirements for adding sites had major budget implications for the CCC.
Characteristics of the CAPTION study PIs and IRBs, as well as the estimated time spent on
the initial IRB submission and the first continuing review, are shown in Table 1.
Respondents were predominantly affiliated with an academic institution (95.2%), and the
position held by most respondents (90.5%) included an expectation for research and/or
scholarship. The majority of respondents (71.4%) used a computer-based IRB system, and
only a minority of respondents (19.0%) had administrative support for assisting with the
IRB process.
During the initial IRB submission as well as the first continuing review, a number of diverse
and disparate issues arose with various subcontracted study sites (Table 2). These included
issues related to bias regarding the source of the application, study design, assessment
instruments, access to patient records, study procedures, Spanish-only speaking subjects,
role of site researchers and physicians, interdepartmental or administrative concerns,
questions regarding updates to site operations manuals, and delays in providing researchers
with updated consent documents.
The perceptions of subcontracted study sites (site PIs) related to the level of difficulty with
initial and first continuing IRB approval, willingness to participate in future PBRN studies
as either a PI or collaborating investigator (non-PI), and amount of time initially anticipated
for navigating the IRB process are shown in Table 3.
A correlational analysis was conducted to determine if associations existed between any of
the variables obtained from the survey of CAPTION study PIs. Bivariate analyses yielded a
number of significant correlations, particularly with regard to the perceived level of
difficulty in obtaining initial IRB approval, level of difficulty associated with the first
continuing review, willingness to serve again as a PI, and willingness to participate in a
future PBRN study due to the IRB process (Table 4).
Availability of research support was not associated with perceived difficulty in obtaining
initial or continuing IRB approval, or with willingness to either serve again as a site PI or
participate in another PBRN study in the future. However, the more research projects that an
individual had served on as a PI or co-PI, the less IRB procedures dissuaded the PI from
participating in a PBRN study in the future (rS = 0.531, p = 0.016). The perceived level of
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difficulty in obtaining initial IRB approval was greater for those with computer-based
systems than for those with paper-based systems (rRB = 0.589, p = 0.005).
The type of IRB (i.e., both university and hospital/health systems vs. others) was not
associated with the perceived difficulty required for initial or continuing IRB approval, or
with the willingness of an individual to participate in a future PBRN study (Mann Whitney
U, p > 0.05 for all 3 tests). The type of IRB was not associated with estimated hours spent
on initial or continuing IRB approval (Mann Whitney U, p > 0.05 for both tests).
Discussion
Navigating the IRB process during the CAPTION study was much more challenging and
time consuming for the participating site PIs than expected, even for more seasoned
investigators who had been involved with many prior research studies. In fact, many of these
barriers would likely not be limited to PBRN-focused research. However, despite the effort
and challenges encountered in the current PBRN study, most of these investigators would
still agree to participate in the CAPTION trial if invited again. This latter finding may have
been due to the fact that centralized staff at the CCC prepared IRB templates, assisted with
navigating the IRB process for newer investigators, and helped address the numerous
questions and issues raised by the 28 IRBs. It is likely that if this centralized support were
not available, many investigators would be less likely to participate in the future. It should
be noted that very few studies conducted in PBRNs have the finances to support the
infrastructure developed for the CAPTION trial, whose substantial budget was funded by the
NIH. These identified IRB barriers and issues required a great deal of time for the CCC
staff, and streamlining the IRB process could reduce these large budgetary requirements.
A unique aspect of the current study is that a formal analysis was conducted to assess if
correlations existed between various factors associated with the IRB process and PI
characteristics and perceptions. Interestingly, despite a relatively low number of study PIs
(21 of 28 surveyed [75% response rate]), several correlations were significant. The greater
the difficulty in obtaining initial and continuing IRB approval, the less willing the individual
was to serve as a PI in the future. More generally, the willingness of an individual to serve in
any capacity on any future PBRN study was inversely related to the perceived difficulty of
obtaining both initial (rS = −0.511, p = 0.021) and continuing (rS = −0.824, p < 0.001) IRB
approval. While others have identified IRB challenges as barrier for participating in PBRN
research19, 25, scant data are available formally assessing PI perceptions.19 These findings
are concerning, considering the great need for continued and expanded research assessing
different models of care, particularly in the primary care setting and involving traditionally
underrepresented patient populations.
A potential solution to many of the IRB hurdles encountered in multicenter studies, whether
through a formal PBRN or outside of a PBRN, is the use of a central IRB. In July 2011, the
Office of the Secretary of the Department of Health and Human Services and Office of
Science and Technology Policy issued an advance notice of proposed rulemaking for
comment related to human research subjects protection,26 with the opportunity for comment
extended to October 26, 2011.27 One of the proposed rules being considered was mandating
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that all domestic multicenter studies rely on a single IRB as the IRB of record. Solicitation
for comments and recommendations specifically related to this proposed rule included
advantages and disadvantages of mandating a single IRB for multicenter studies as opposed
to “encouraging” how local IRB review either adds or detracts from human protections and
institutional views and ethics, legal liability, inefficiencies of local IRB review of
multicenter studies, and methods by which an IRB of record would be selected.26 Final
decisions regarding the proposed rules are currently pending.
Experience with the CAPTION study identified several solutions to overcoming barriers and
delays in the IRB approval process. Depending on the level of budgetary support given to a
study’s central coordinating team, additional strategies for improving success with IRB
processes associated with any PBRN study, beyond those used in the CAPTION study,
would include the following:
• Set a series of deadlines for a preliminary draft of the IRB application, final
submission, and IRB approval. Send reminders of those deadlines and inform sites
that those that fail to meet the schedule of deadlines will be dropped. Sites that
have substantial difficulty meeting these deadlines are likely to have difficulty
meeting other study requirements.
• Consider having several additional clinics in reserve or as alternates that can be
quickly added if initial sites or their IRBs have unacceptable delays in approval.
• Schedule one or more conference calls with the individual at each site who is
working on the initial IRB application. During the call, review drafted IRB
materials and devise an early strategy to deal with potential problems.
• If the study includes oversight by study monitors from the data coordinating center,
these monitors should be included on the local IRB forms to facilitate examination
of medical records during monitoring site visits. Have each site obtain IRB
approval for both the study coordinator and the monitor from the CCC to have full
access to subject medical record data. Have sites explicitly include this as a
condition of participation in the study.
• Select study principal investigators with a track record of successful research.
Seasoned investigators will likely have significantly more experience navigating
the IRB process and dealing with various barriers.
There are limitations with this analysis of IRB challenges associated with the CAPTION
study. First, the vast majority (95.2%) of PIs who responded to the PI survey had an
academic appointment and research and/or scholarship as an expectation of their position.
Thus, the external validity of some of the findings may be questioned. However, the
distribution of primary care study sites across the country and inclusion of minorities and
underserved patient populations strengthen the study’s external validity. It is likely that there
would be even greater barriers in settings not affiliated with academic settings and with PIs
who have not conducted previous research. This finding questions whether the hope for
PBRNs to include true community-based medical offices can be realized if these IRB
challenges remain. Second, a formal systematic process for tracking time and effort required
for IRB approvals was not conducted a priori. Thus, it is possible that errors and/or
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inaccuracies may exist in some responses obtained from the PI survey. Despite these
limitations, the study findings corroborate many perceptions related to challenges with
multicenter studies and IRB approval noted previously in the literature.10–18
Conclusion
A number of challenges related to local IRB approval were encountered during the
CAPTION study. These included bias regarding source of application, issues relating to
study design, study instruments, study procedures, access to patient records, Spanish-only
speaking subjects, role of clinic physicians, interdepartmental concerns, and problems at the
time of continuing review. Most issues or concerns were adequately resolved. However, the
time and resources required to do this decreased the willingness of some site PIs to
participate in future PBRN projects. This is an unfortunate finding in an era where research
evaluating different forms of health care delivery in a primary care setting is sorely needed.
Moreover, challenges with local IRBs can add considerable cost to practice-based research
at a time when federal agencies have difficulty funding such studies and can also delay
progress with the overall progress of the study. Hopefully, proposed rule changes regarding
protection of human subjects in community-based research will make conducting PBRN
studies less arduous from an IRB perspective, especially for inclusion of nonacademic
practice sites.
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Table 1
Characteristics of the CAPTION study PIs and IRBsa
Characteristic Value
Position type
 Academic 20 (95.2)
 Nonacademic 1 (4.8)
Had research and/or scholarship expectation for current position 19 (90.5)
Number of research projects involved with as a PI or co-PI
 < 5 9 (42.9)
 5-10 7 (33.3)
 11-20 3 (14.3)
 > 20 2 (9.5)
Had administrative support for assisting with IRB process 4 (19.0)
Had computer-based IRB system 15 (71.4)
Type of IRB
 University 6 (28.6)
 Hospital/Health system 2 (9.5)
 Both University and Hospital/Health System 12 (57.1)
 Community 1 (4.8)
Estimated time spent on initial IRB application (hours) 20 ± 16.4*
(range 0-50)
Estimated time spent on first continuing review application (hours) 5 ± 4.5*
(range 0-20)
Data are no. (%) of respondents or mean ± SD values.
a
21 of 28 PIs surveyed responded.
*
Estimated time required for each PI to complete the IRB process; does not include the time required by the staff at the CCC to assist the local PIs.
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Table 3
Results from the PI Surveya
Statement Level of agreement
Obtaining initial IRB approval for the CAPTION study was difficult. 3.0 (3.0)
Obtaining continuing IRB approval for the CAPTION study was difficult. 2.0 (1.0)
If invited to participate in the CAPTION study again as a site PI, I would
participate.
5.0 (1.5)
If invited to participate in the CAPTION study again, but as a
collaborating investigator and not a site PI, I would participate.
4.5 (1.0)
The IRB process would not dissuade me from participating in a future
PBRN research study.
4.0 (2.5)
Navigating the IRB process was more time consuming than I had
anticipated.
4.0 (2.5)
Data are median (interquartile range) values of responses indicated on 5-point Likert scale: 5 = strongly agree, 4 = agree, 3 = neutral, 2 = disagree,
1 = strongly disagree.
a
21 of 28 PIs surveyed responded; not all respondents answered all questions.
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“Obtaining initial IRB approval was difficult” correlated with:
   Obtaining continuing IRB approval was difficult 0.713 <0.001
   Would serve again as site PI −0.599 0.004
   IRB process would not dissuade me from a future study −0.511 0.021
   IRB process more time consuming than anticipated 0.711 <0.001
   IRB application is computer-based 0.589 0.005
   Time in hours spent on initial application 0.454 0.039
“Obtaining first IRB continuing review approval was difficult” correlated with:
   Would serve again as PI −0.464 0.034
   IRB process would not dissuade me from a future study −0.824 <0.001
   IRB process more time consuming than anticipated 0.464 0.034
   Time in hours spent on first continuing review 0.517 0.016
“I would serve again as site PI” correlated with:
   Would serve as a collaborating investigator 0.722 <0.001
   IRB application is computer-based −0.480 0.028
“The IRB process would not dissuade me from participating in a future PBRN study” correlated with:
   IRB process more time consuming than anticipated −0.591 0.006
   Number of research projects involved with as PI or co-PI 0.531 0.016
   Estimated hours spent on the initial IRB application −0.444 0.05
   Estimated hours spent on first continuing review application −0.535 0.015
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